IDL Diagnostics AB (publ)

IDLDX · Nasdaq Stockholm · Healthcare

0.37SEK +2.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: −2.6%

Performance

1 month

−8.0%

1 year

−2.6%

3 years, per year

−9.9%

5 years, per year

−24.6%

Largest fall, 3 years

−95.1%

Below the peak now

−97.7%

Volatility, 1 year

78.8%

Return with dividends reinvested.

Key figures

P/E

5.4

P/B

0.6

Dividend yield

0.0%

Return on equity

+10.2%

Net margin

+25.8%

Market value

8 m USD

Quality, value and trend

Where IDL Diagnostics stands against every Nordic stock today. 100 is best.

Quality96

Profitability and a sound balance sheet over time. Better than 96% of Nordic stocks.

Value96

The price measured against earnings, assets and cash flow. Better than 96% of Nordic stocks.

Trend62

The price development over the past year. Better than 62% of Nordic stocks.

Combined98

Quality, value and trend together. Better than 98% of Nordic stocks.

About IDL Diagnostics

IDL Diagnostics AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 25 employees.

IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025. IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis